STAT

Amicus Therapeutics acquires portfolio of gene therapies targeting neurologic disorders

Source: Eric Piermont/AFP/Getty Images

Amicus Therapeutics is expanding the focus its drug development work with the purchase of a portfolio of early-stage gene therapies targeting rare neurologic diseases, the company announced Thursday.

Two of the 10 gene therapies programs being acquired by Amicus have already entered human clinical trials as potential, one-time cures for different forms

You're reading a preview, sign up to read more.

More from STAT

STAT4 min readSociety
How Europe Is Building A Sweeping System To Study Medication Safety In Pregnant And Lactating Women
More than 88 organizations have joined a sweeping new effort in Europe to tackle the research gaps on medication use in pregnant and lactating women.
STAT4 min read
Alarmed By New ‘CRISPR Babies’ Plan, Top Science Figures Say They’re Powerless To Stop It
Outraged by a new plan to create "CRISPR babies" in Russia, leading science figures concede that their organizations are powerless to stop it.
STAT1 min read
Listen: A Controversial Desire Drug, Courtroom Genealogy, & The Quest For Longer Life
Is desire a matter of medicine? Can you convict on genealogy? And what do you get the alleged bride who has it all? We discuss all that and more on the latest episode of “The Readout LOUD,” STAT’s biotech podcast. First, we discuss a new drug meant t